https://www.live-feeds.com/feed/us-regulator-orders-makers-of-weight-loss-drugs-to-carry-blindness-risk-warningContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/us-regulator-orders-makers-of-weight-loss-drugs-to-carry-blindness-risk-warninghttps://www.live-feeds.com/feed/us-regulator-orders-makers-of-weight-loss-drugs-to-carry-blindness-risk-warning#u197614Thu, 12 Nov 2026 20:39:36 +0000The U.S. Food and Drug Administration has mandated that manufacturers of popular GLP-1 weight-loss and diabetes drugs add a warning about a rare eye condition that can cause sudden vision loss. The label change applies to blockbuster medications including Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Zepbound and Mounjaro. The condition, non-arteritic anterior ischemic optic neuropathy (NAION), reduces blood flow to the optic nerve and can result in permanent blindness. The FDA determined the risk warrants a warning after reviewing adverse event reports, though the agency maintai